JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

Benzinga · 1d ago
JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $76 to $83.